As COVID-19 continues to disrupt communities around the world, IVI remains committed to our mission to protect the world’s most vulnerable people from vaccine-preventable diseases by developing safe, effective, and affordable vaccines for global health. We do this for diseases like cholera and typhoid, as well as emerging infectious diseases.
IVI is not pursuing its own COVID-19 vaccine and has chosen to partner with vaccine developers in Korea and globally to accelerate multiple safe and effective vaccines as efficiently as possible. We are conducting early-stage clinical trials, establishing vaccine evaluation systems and developing COVID-19 vaccine adjuvants in addition to epidemiological studies.
This study is supported by the Coalition for Epidemic Preparedness Innovations (CEPI).
This study is supported by the Swedish International Development Cooperation Agency.
This work is supported by the Bill & Melinda Gates Foundation.
All of our work is made possible by core and project funding from the governments of South Korea, Sweden, India, and Finland; foundations; global health partners; and generous individuals. In unstable times, we’re grateful for these partnerships and proud to do our part in responding to the global health crisis we face today. Join us.